Claims for Patent: 11,124,526

Summary for Patent: 11,124,526

Title:	Crystalline beta-lactamase inhibitor
Abstract:	A crystalline compound of formula (I):The compound of formula (I) is a β-lactamase inhibitor and may be administered in combination with an antibacterial agent for prevention or treatment of bacterial infection.
Inventor(s):	Alessandro Lamonica, Marco Forzatti, Stefano Biondi
Assignee:	Allecra Therapeutics SAS
Application Number:	US16/177,406
Patent Claims:	1. A crystalline compound of formula (I): wherein the compound has an XRPD spectrum comprising four or more peaks selected from peaks with 2θ angles of: 8.82, 12.07, 14.43, 14.92, 16.26, 18.25, 19.06, 19.78, 20.82 and 23.51±0.1 degrees 2θ; or four or more peaks selected from peaks with 2θ angles of: 9.33, 10.73, 14.85, 15.29, 15.77, 16.16, 18.60, 20.12, 21.00 and 23.22±0.1 degrees 2θ; or four or more peaks selected from peaks with 2θ angles of: 6.7824, 15.4567, 16.3961, 17.1082, 20.0651, 20.6373, 23.2376, 23.6811, 26.1802 and 32.4753±0.05 degrees 2θ; or four or more peaks selected from peaks with 2θ angles of: 6.8269, 15.0475, 15.6848, 16.4735, 17.1773, 18.4488, 20.6999, 23.3436, 23.8843 and 25.3818±0.05 degrees 2θ. 2. A crystalline compound according to claim 1, with an XRPD spectrum substantially as shown in FIG. 1. 3. A crystalline compound according to claim 1, the compound having a Thermo Gravimetric Analysis (TGA) curve showing an endothermic event at about 163° C.±2° C. 4. A crystalline compound according to claim 1, the compound having a Differential Scanning calorimetry (DSC) curve showing an endothermic event at about 163° C.±2° C. 5. A crystalline compound of formula (I): wherein the compound has an XRPD spectrum comprising four or more peaks selected from peaks with 2θ angles of: 9.37, 10.34, 12.59, 13.17, 15.00, 15.63, 18.51, 19.10, 20.79 and 23.93±0.10 degrees 2θ. 6. A crystalline compound according to claim 5, the compound having an XRPD spectrum substantially as shown in FIG. 2. 7. A crystalline compound according to claim 5, the compound having a Thermo Gravimetric Analysis (TGA) curve showing an endothermic event at about 155° C.±2° C. 8. A crystalline compound according to claim 5, the compound having a Differential Scanning calorimetry (DSC) curve showing an endothermic event at about 180° C.±2° C. 9. A crystalline compound of formula (I): wherein the compound has an XRPD spectrum comprising four or more peaks selected from peaks with 2θ angles of: 12.7398, 15.3615, 15.9547, 16.4290, 18.1207, 20.4870, 22.8548, 23.2204, 27.0457, 27.6934 and 32.4785±0.05 degrees 2θ. 10. A crystalline compound according to claim 9, the compound having an XRPD spectrum substantially as shown in FIG. 29. 11. A crystalline compound according to claim 9, the compound having a Thermo Gravimetric Analysis (TGA) curve showing an endothermic event at about 160° C. 12. A crystalline compound according to claim 9, the compound having a DSC profile showing an exothermic peak at approximately 184° C. 13. A process for preparing a crystalline compound, the process comprising the steps of: forming a formulation by dissolving or suspending an amorphous compound of formula (I) in a solvent consisting of N,N-dimethylformamide; and crystallizing the compound of formula (I) from the formulation; wherein the compound has an XRPD spectrum comprising four or more peaks selected from peaks with 2θ angles of: 12.73±0.05 degrees 2θ, 15.36±0.05 degrees 2θ, 15.95±0.05 degrees 2θ, 16.42±0.05 degrees 2θ, 18.12±0.05 degrees 2θ, 20.48±0.05 degrees 2θ, 22.85±0.05 degrees 2θ, 23.22±0.05 degrees 2θ, 27.04±0.05 degrees 2θ, 27.69±0.05 degrees 2θ and 32.47±0.05 degrees 2θ. 14. A method of treating a bacterial infection comprising administering to a patient in need thereof a therapeutically effective amount of a pharmaceutical composition comprising a crystalline compound according to claim 9. 15. A method of treating a bacterial infection comprising co-administering to a patient in need thereof a therapeutically effective amount of a pharmaceutical composition comprising a crystalline compound according to claim 9 and a therapeutically effective amount of an antiobiotic. 16. The process according to claim 13, wherein crystals are allowed to form from the solution for more than four hours before separation of crystals from the solvent. 17. The process according to claim 13, wherein crystals are allowed to form from the solution for at least six hours before separation of crystals frorm the solvent. 18. The process according to claim 17, wherein the temperature of the solution is reduced while the crystals are allowed to form.